To include your compound in the COVID-19 Resource Center, submit it here.

AVP-786: Phase I data

Data from 36 healthy volunteers in the first stage of a double-blind, crossover Phase I trial showed that AVP-786 plus low-dose quinidine had a comparable pharmacokinetic, safety and tolerability profile to that of AVP-923, a combination product containing dextromethorphan

Read the full 392 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers